A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer

Annals of Oncology

Volumn 9, Issue 11, 1998, Pages 1247-1249

  Gelmon, K A ^a,b   Tolcher, A ^a   O'Reilly, S ^a   Campbell, C ^a   Bryce, C ^a   Shenkier, T ^a   Ragaz, J ^a   Ayers, D ^a   Nakashima, L ^a   Rielly, S ^a   Dulude, H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Metastatic breast cancer; Paclitaxel; Scheduling

Indexed keywords

PACLITAXEL;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MYALGIA; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 7844239773     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008445123416     Document Type: Article

References (12)

1. Arbuck S, Canetta R, Onetto N et al. Current dosage and schedule issues in the development of paclitaxel. Semin Oncol 1993; 20: 31-9.
2. Perez T, Sulkes A, Chollet P et al. a multicentred randomized study of two schedules of paclilaxel in patients with advanced breast cancer. Eur j Cancer 1995; 31A (Suppl 5): 575 (Abstr 345).
3. Wilson WH, Berg S, Bryant GB et al. Paclitaxel in doxorubicin-refractory or mitoxantrone -refractory breast cancer: A phase I-II study of 96-hour infusion. J Clin Oncol 1994; 12: 1621 9.
4. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by one-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13: 1609 14.
5. Breier S, Lebedinsky C, Ayivri C et al. Long-term weekly paclitaxel in metastatic breast cancer - A phase II trial in pretreated patients. Proc ASCO 1998 (Abstr 740).
6. Gelmon KA, O'Reilly S, Tolcher AW et al. Phase I-II trial of bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185 91.
7. Miller AB, Hoogstraten b. Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
8. Trudeau ME, Eisenhauer EA, Higgins BP. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
9. Chan S, Friedrichs K, Noel D et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients with metastatic breast cancer who have failed an alkylating containing regimen: Preliminary results. Proc Am Soc Clin Oncol 1997; 16: 154a (Abstr).
10. Sparano JA, Neuberg D, Glick JH et al. Phase II trial of bi-weekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1997; 15 (5): 1880-4.
11. McCaskill Steven W. Ansari R, Fisher W et al. Phase II study of bi-weekly cisplatin and paclitaxel in the treatment of metastatic breast cancer. Proc ASCO 1996; 15: A144 (Abstr).
12. Baselga J, Seidman AD, Rosen PP et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology 1997; II (3 Suppl 2): 43 8.